Equon Pharmaceuticals is engaged in the development of novel therapies targeting Late-Phase Asthmatic Response and Rheumatoid Arthritis, employing Human Monoclonal Antibody technology to block the inflammatory process.

Equon's goal is to offer a new class of drugs for the symptomatic relief of the pain and suffering caused by these conditions.

Equon's therapeutics are directed at the immune response sequence which, in asthmatics and arthritics, proceeds out of the normal control of the self-regulated immune system, resulting in damage to body tissue and joints. Recently published scientific research studies have identified the cells and receptors involved in these sequences and provide the basis for Equon’s development efforts.